Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...

Welcome to today’s Biotech Spotlight, a series featuring companies that are creating breakthrough technologies and products. Today, we’re looking at Anokion, a Swiss biotech pioneering a vaccine to ...

A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...

Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

French drugmaker Sanofi has been playing the long game when it comes to the blockbuster Dupixent, and the results are starting to show. First approved for atopic dermatitis in 2017, the skin and ...

Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...